The median overall survival was 37.5 months (95% CI, 25.5 months–not reached) in the nivolumab group and 11.2 months (95% CI, 9.6-13.0 months) in the dacarbazine group (hazard ratio, 0.46; 95% CI, 0.36-0.59; P < .001). Complete and partial responses, respectively, were reported for 19.0% (40 of 210) and 23.8% (50 of 210) of patients in the nivolumab group compared with 1.4% (3 of 208) and 13.0% (27 of 208) of patients in the dacarbazine group....Nivolumab led to improved 3-year overall survival vs dacarbazine in patients with previously untreated BRAF wild-type advanced melanoma.

...BRAF status must be determinate but patient will be eligible regardless the status (BRAF wildtype and BRAF V600 mutation positive patients could be included) 9....

...- Known BRAF wild-type, as per regionally acceptable V600 mutational status testing....

We present the case of a 75-year-old man with metastatic melanoma who underwent 95 cycles of nivolumab...a biopsy of the dorso-lumbar spine was performed, which established that the bone lesions were metastases of melanoma, BRAF negative. Therefore, in January 2018, we decided to initiate monotherapy with nivolumab 240 mg every two weeks, and zoledronic acid 4 mg every four weeks....After six doses of nivolumab, the pain was controlled, and the patient recovered from the motor deficit....it was interpreted as partial remission.